Revier Therapeutics
Announced 28 Aug 2026$6.9M ยท Seed ยท Hospitals and Health Care ยท Germany
Revier has established the first therapeutic approach to selectively target class IIa HDACs to treat cardiometabolic diseases.
โ๐จ BREAKING NEWS: Revier Therapeutics Raises โฌ6 Million!In an exciting development for the biotech sector, Revier Therapeutics is making waves with its innovative approach to cardiometabolic therapies. Led by Prof. Eva van Rooij, this Heidelberg-based startup is tackling heart failure and cardiovascular diseases with precision-targeted treatments.โ
6 more sources tracked. Read the full press release and reporter coverage.
Sign up to read โInvestors: KHAN Technology Transfer Fund II.